The acknowledgement of cancer immunotherapy as breakthrough of the year in 2013 and the award of the Nobel Prize 2018 for the discoveries of anti-CTLA4 and anti-PD-1 as cancer immunotherapy illustrate the paradigm shift in the treatment of cancer patients [4,5]. This evidence concerns the gene PDCD1 and cancer.